StemCyte Launches CordBloodTV Full Service, Globally Dedicated Information Resource on Cord Blood Advances
COVINA, Calif., March 21, 2011 /PRNewswire/ -- California-based StemCyte, Inc. announces the launch of www.cordbloodtv.com, a first-of-its-kind video cord blood banking education resource. StemCyte offers this comprehensive educational tool that allows audiences worldwide to watch and learn about private and public cord blood banking options and the latest in medical research and treatments that use umbilical cord blood stem cells.
"StemCyte is pleased to offer our worldwide audience CordBloodTV, the most comprehensive video resource for cord blood banking education," said Calvin Cole, StemCyte's President, North America. "We aim to compile in one easily accessible location the best information available for parents, physicians, researchers and transplant experts wishing to learn more about the state of the art in cord blood."
CordBloodTV offers educational videos, news and personal stories, expert dialogue and more, all offering insight into the potentially lifesaving medical resource of umbilical cord stem cells. The new website illustrates StemCyte's continuing commitment to increasing global public awareness regarding the science and substance of umbilical cord blood banking, related research and advances in life-saving therapies. In the future CordBloodTV will include interviews, presentations from expert authorities and by researchers worldwide who are investigating the potential of stem cells derived from cord blood to treat devastating illnesses.
About StemCyte, Inc.
Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over 1,400 cord blood products for over 40 life-threatening diseases to over 200 leading worldwide transplant centers. StemCyte is actively involved in the development of new umbilical cord blood-based cell therapies. The Company supports the largest clinical study for using unrelated cord blood transplantation for thalassemia, one of the most common genetic diseases in the world, and the developments of trials investigating regenerative spinal cord therapies. StemCyte is one of the only for-profit companies contracted by the US Department of HHS to help contribute clinical grade cord blood units to the public National Cord Blood Inventory for unrelated transplants. Its headquarters are located in Covina, Ca. and Ewing, NJ. To learn more visit www.StemCyte.com.
SOURCE StemCyte, Inc.